Annual Accounts Receivable
$3.41 B
-$288.00 M-7.79%
31 December 2023
Summary:
Teva Pharmaceutical Industries Limited annual accounts receivable is currently $3.41 billion, with the most recent change of -$288.00 million (-7.79%) on 31 December 2023. During the last 3 years, it has fallen by -$1.17 billion (-25.61%). TEVA annual accounts receivable is now -54.70% below its all-time high of $7.52 billion, reached on 31 December 2016.TEVA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$3.46 B
-$304.00 M-8.07%
30 September 2024
Summary:
Teva Pharmaceutical Industries Limited quarterly accounts receivable is currently $3.46 billion, with the most recent change of -$304.00 million (-8.07%) on 30 September 2024. Over the past year, it has increased by +$77.00 million (+2.27%). TEVA quarterly accounts receivable is now -57.11% below its all-time high of $8.07 billion, reached on 30 September 2016.TEVA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TEVA Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.8% | +2.3% |
| 3 y3 years | -25.6% | -14.4% |
| 5 y5 years | -41.5% | -34.1% |
TEVA Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -25.6% | at low | -23.6% | +2.3% |
| 5 y | 5 years | -41.5% | at low | -39.0% | +2.3% |
| alltime | all time | -54.7% | +843.3% | -57.1% | +858.2% |
Teva Pharmaceutical Industries Limited Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.46 B(-8.1%) |
| June 2024 | - | $3.77 B(+9.0%) |
| Mar 2024 | - | $3.46 B(+1.4%) |
| Dec 2023 | $3.41 B(-7.8%) | $3.41 B(+0.7%) |
| Sept 2023 | - | $3.38 B(-4.4%) |
| June 2023 | - | $3.54 B(+3.0%) |
| Mar 2023 | - | $3.44 B(-7.1%) |
| Dec 2022 | $3.70 B(-18.4%) | $3.70 B(-0.9%) |
| Sept 2022 | - | $3.73 B(-16.6%) |
| June 2022 | - | $4.47 B(+5.1%) |
| Mar 2022 | - | $4.25 B(-6.1%) |
| Dec 2021 | $4.53 B(-1.1%) | $4.53 B(+11.9%) |
| Sept 2021 | - | $4.05 B(-9.8%) |
| June 2021 | - | $4.49 B(-1.8%) |
| Mar 2021 | - | $4.57 B(-0.2%) |
| Dec 2020 | $4.58 B(-19.3%) | $4.58 B(+4.5%) |
| Sept 2020 | - | $4.38 B(-3.5%) |
| June 2020 | - | $4.54 B(-12.4%) |
| Mar 2020 | - | $5.19 B(-8.6%) |
| Dec 2019 | $5.68 B(-2.5%) | $5.68 B(+8.0%) |
| Sept 2019 | - | $5.25 B(-0.1%) |
| June 2019 | - | $5.26 B(+3.0%) |
| Mar 2019 | - | $5.11 B(-12.3%) |
| Dec 2018 | $5.82 B(-18.3%) | $5.82 B(+2.8%) |
| Sept 2018 | - | $5.67 B(-6.5%) |
| June 2018 | - | $6.06 B(-3.6%) |
| Mar 2018 | - | $6.29 B(-11.8%) |
| Dec 2017 | $7.13 B(-5.3%) | $7.13 B(-4.0%) |
| Sept 2017 | - | $7.42 B(+1.4%) |
| June 2017 | - | $7.32 B(+0.8%) |
| Mar 2017 | - | $7.26 B(-3.4%) |
| Dec 2016 | $7.52 B(+40.6%) | $7.52 B(-6.8%) |
| Sept 2016 | - | $8.07 B(+50.2%) |
| June 2016 | - | $5.37 B(+3.6%) |
| Mar 2016 | - | $5.19 B(-3.0%) |
| Dec 2015 | $5.35 B(-1.1%) | $5.35 B(+1.4%) |
| Sept 2015 | - | $5.28 B(-5.3%) |
| June 2015 | - | $5.57 B(+1.1%) |
| Mar 2015 | - | $5.51 B(+1.8%) |
| Dec 2014 | $5.41 B(+1.3%) | $5.41 B(-0.0%) |
| Sept 2014 | - | $5.41 B(+0.4%) |
| June 2014 | - | $5.39 B(+2.2%) |
| Mar 2014 | - | $5.28 B(-1.2%) |
| Dec 2013 | $5.34 B(-4.2%) | $5.34 B(+2.8%) |
| Sept 2013 | - | $5.19 B(-2.1%) |
| June 2013 | - | $5.30 B(-2.0%) |
| Mar 2013 | - | $5.42 B(-2.8%) |
| Dec 2012 | $5.57 B | $5.57 B(-3.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $5.78 B(+6.5%) |
| June 2012 | - | $5.43 B(-10.3%) |
| Mar 2012 | - | $6.06 B(-2.5%) |
| Dec 2011 | $6.21 B(+13.5%) | $6.21 B(+10.8%) |
| Sept 2011 | - | $5.61 B(+2.5%) |
| June 2011 | - | $5.47 B(-1.9%) |
| Mar 2011 | - | $5.58 B(+1.8%) |
| Dec 2010 | $5.48 B(+9.1%) | $5.48 B(+4.7%) |
| Sept 2010 | - | $5.23 B(+4.9%) |
| June 2010 | - | $4.99 B(-2.9%) |
| Mar 2010 | - | $5.14 B(+2.3%) |
| Dec 2009 | $5.02 B(+7.9%) | $5.02 B(+7.0%) |
| Sept 2009 | - | $4.69 B(+7.2%) |
| June 2009 | - | $4.38 B(+5.9%) |
| Mar 2009 | - | $4.13 B(-11.2%) |
| Dec 2008 | $4.65 B(+31.2%) | $4.65 B(+18.8%) |
| Sept 2008 | - | $3.92 B(+3.5%) |
| June 2008 | - | $3.78 B(+5.1%) |
| Mar 2008 | - | $3.60 B(+1.5%) |
| Dec 2007 | $3.55 B(+21.4%) | $3.55 B(+8.2%) |
| Sept 2007 | - | $3.28 B(+7.4%) |
| June 2007 | - | $3.05 B(+10.1%) |
| Mar 2007 | - | $2.77 B(-5.1%) |
| Dec 2006 | $2.92 B(+65.2%) | $2.92 B(-21.0%) |
| Sept 2006 | - | $3.70 B(+3.2%) |
| June 2006 | - | $3.58 B(+66.2%) |
| Mar 2006 | - | $2.16 B(+21.9%) |
| Dec 2005 | $1.77 B(+19.9%) | $1.77 B(+11.4%) |
| Sept 2005 | - | $1.59 B(+3.8%) |
| June 2005 | - | $1.53 B(-5.7%) |
| Mar 2005 | - | $1.62 B(+9.9%) |
| Dec 2004 | $1.48 B(+43.1%) | $1.48 B(+6.0%) |
| Sept 2004 | - | $1.39 B(+6.8%) |
| June 2004 | - | $1.30 B(+6.8%) |
| Mar 2004 | - | $1.22 B(+18.2%) |
| Dec 2003 | $1.03 B(+20.6%) | $1.03 B(+15.4%) |
| Sept 2003 | - | $894.30 M(+5.0%) |
| June 2003 | - | $851.60 M(+3.6%) |
| Mar 2003 | - | $822.40 M(-3.9%) |
| Dec 2002 | $855.80 M(+31.4%) | $855.80 M(+23.1%) |
| Sept 2002 | - | $695.40 M(-0.1%) |
| June 2002 | - | $696.10 M(+8.2%) |
| Mar 2002 | - | $643.10 M(-1.2%) |
| Dec 2001 | $651.19 M(+19.8%) | $651.19 M(+10.1%) |
| Sept 2001 | - | $591.40 M(-1.4%) |
| June 2001 | - | $600.08 M(+4.1%) |
| Mar 2001 | - | $576.45 M(+6.0%) |
| Dec 2000 | $543.66 M(+50.5%) | $543.66 M(+50.5%) |
| Dec 1999 | $361.29 M | $361.29 M |
FAQ
- What is Teva Pharmaceutical Industries Limited annual accounts receivable?
- What is the all time high annual accounts receivable for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited annual accounts receivable year-on-year change?
- What is Teva Pharmaceutical Industries Limited quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited quarterly accounts receivable year-on-year change?
What is Teva Pharmaceutical Industries Limited annual accounts receivable?
The current annual accounts receivable of TEVA is $3.41 B
What is the all time high annual accounts receivable for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high annual accounts receivable is $7.52 B
What is Teva Pharmaceutical Industries Limited annual accounts receivable year-on-year change?
Over the past year, TEVA annual accounts receivable has changed by -$288.00 M (-7.79%)
What is Teva Pharmaceutical Industries Limited quarterly accounts receivable?
The current quarterly accounts receivable of TEVA is $3.46 B
What is the all time high quarterly accounts receivable for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high quarterly accounts receivable is $8.07 B
What is Teva Pharmaceutical Industries Limited quarterly accounts receivable year-on-year change?
Over the past year, TEVA quarterly accounts receivable has changed by +$77.00 M (+2.27%)